ELI LILLY & Co is 760.6x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($1.093 T vs $1.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KALV | LLY |
|---|---|---|
| Market cap | $1.44 B | $1.093 T |
| US-listed rank | #2377 | #11 |
| Revenue (latest FY) | $50.00M | $65.18B |
| Net income (latest FY) | -$183.40M | $20.64B |
| Net margin | -366.8% | 31.7% |
| P/E (trailing FY) | - | 53.0 |
| SEC filings | 834 | 989 |
ELI LILLY & Co is 760.6x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($1.093 T vs $1.44 B).
Full pages: KalVista Pharmaceuticals, Inc. and ELI LILLY & Co, or browse the full rankings.